| (210) | Number of the EPO application | 20722936 |
| (220) | Filing date of the EPO application | 2020.04.10 |
| (80) | EPO patent specification publication (B) | EPB nr. 36/2023, 2023.09.06 |
| (110) | EPO patent number | 3856341 |
| (21) | Number of the application | e 2021 0741 |
| (71) | Name(s) of applicant(s), code of the country | BLUEPRINT MEDICINES CORPORATION, US; |
| (72) | Name(s) of inventor(s), code of the country | WAETZIG Joshua D., US;
MAR Brenton, US;
HEINRICH Brian, US;
WILKIE Gordon, US;
MACEACHERN Lauren, CA; |
| (73) | Name(s) of owner(s), code of the country | BLUEPRINT MEDICINES CORPORATION, US; |
| (54) | Title of the invention | CRYSTALLINE FORMS OF (S)-1-(4-FLUOROPHENYL)-1-(2-(4-(6-(1-METHYL-1H-PYRAZOL-4-YL)PYRROLO[2,1-F][1,2,4]TRIAZIN-4-YL)PIPERAZINYL)-PYRIMIDIN-5-YL)ETHAN-1-AMINE AND METHODS OF MAKING |
| (13) | Kind-of-document code | A1 |
| (51) | International Patent Classification | A61P 17/00 (2006.01.01); A61P 35/00 (2006.01.01); A61P 35/02 (2006.01.01); C07D 487/04 (2006.01.01); A61K 31/519 (2006.01.01) |
| (19) | Country | US |
| (41) | Date of publication of the application | 2021.09.30 |
| (30) | Priority | 201962833527 P, 2019.04.12, US; 201962844575 P, 2019.05.07, US; 202062990269 P, 2020.03.16, US |
| (86) | International application | PCT/US2020/027724, 2020.04.10 |
| (87) | International publication | WO 2020/210669, 2020.10.15 |